Chroma Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chroma Therapeutics Limited
The big pharma has returned the global commercial rights to Sareum’s lead program which GSK gained as part of its recently completed acquisition of Sierra Oncology, leaving Sareum scrambling for a new path forward.
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
- Other Names / Subsidiaries
- CTI BioPharma Corporation